Spyre Therapeutics Advances IBD Pipeline with SPY001 and SPY002 Programs
Key Insights
Spyre Therapeutics is progressing its SPY001 program, an anti-a4ß7 monoclonal antibody, with interim Phase I data expected by year-end for IBD treatment.
The company anticipates initiating a Phase I study for its SPY002 program in the second half of 2024, following IND-enabling studies.
SPY003, another IBD program, is on track for development candidate nomination by mid-year and IND-enabling studies in the latter half of 2024.
Spyre Therapeutics Inc. (SYRE) is making strides in its pipeline of next-generation therapeutics for inflammatory bowel disease (search) (IBD), including ulcerative colitis (search) and Crohn's disease (search). The company's lead candidate, SPY001, and the SPY002 program are advancing through clinical and preclinical stages.
SPY001: Phase I Trial Progress
SPY001, a novel subcutaneous extended half-life monoclonal antibody targeting α4β7 integrin (search), is currently in a Phase I trial in healthy volunteers. Integrin α4β7 plays a crucial role in the pathogenesis of IBD. The trial includes single-ascending dose (SAD) and multi-ascending dose (MAD) components, aiming to enroll approximately 48 healthy adults across four SAD cohorts and two MAD cohorts. The primary endpoint is safety, with pharmacokinetics (PK) as a secondary endpoint. Interim safety and PK data are expected by the end of this year. Pending positive data, Spyre anticipates moving SPY001 into Phase II development in 2025.
SPY002: Advancing Towards Clinical Trials
The SPY002 program, also targeting IBD, has nominated two development candidates. These candidates are currently undergoing IND-enabling studies. Spyre anticipates submitting regulatory filings and initiating a Phase I first-in-human study in healthy volunteers in the second half of 2024, pending additional preclinical data and regulatory clearance. Interim data from the Phase I study are expected in the first half of 2025. If successful, one SPY002 candidate will advance to Phase II and potentially Phase III clinical studies to support global regulatory submissions and commercial approval.
SPY003: Development Milestones
Spyre's SPY003 program for IBD is expected to achieve two key milestones this year: development candidate nomination by mid-year and progression to IND-enabling studies in the second half of 2024.
Financial Position
As of March 31, 2024, Spyre Therapeutics reported cash and cash equivalents, marketable securities, and restricted cash totaling $485.0 million. This robust financial position supports the company's ongoing clinical and preclinical development activities.
About Spyre Therapeutics
Spyre Therapeutics was formed as a spinout of Paragon Therapeutics Inc. and reverse-merged with Aeglea BioTherapeutics Inc. (AGLE) on November 28, 2023. The company is now trading on the Nasdaq under the ticker symbol "SYRE". With multiple catalysts expected across its lead programs from late 2024 through 2025, Spyre Therapeutics is positioned for potential value-driving developments in the IBD therapeutic landscape.
IBD Market Overview
IBD, characterized by chronic inflammation of the gastrointestinal tract, includes Crohn's disease (search) and ulcerative colitis (search). Approximately 2.4 million individuals in the U.S. are diagnosed with IBD, with 70,000 new cases each year, highlighting the significant unmet medical need.